Topical Tacrolimus for Parastomal Pyoderma Gangrenosum: A Report of Two Cases
|
|
- Ethel Sutton
- 5 years ago
- Views:
Transcription
1 Topical Tacrolimus for Parastomal Pyoderma Gangrenosum: A Report of Two Cases Maria Altieri, MS; Khashayar Vaziri, MD; and Bruce A. Orkin, MD Abstract Pyoderma gangrenosum (PG) is an idiopathic, ulcerative, inflammatory dermatologic condition that occurs in patients with systemic diseases such as inflammatory bowel disease (IBD). This inflammatory skin disorder is presumably caused by an autoimmune mechanism and the diagnosis is one of exclusion. PG is not a common condition but it is thought to account for approximately 50% of chronic parastomal ulcers. Refractory parastomal PG (PPG) occurs in patients with inactive disease or after bowel resection. Multiple medical treatments, ranging from topical agents for mild disease to systemic immunosuppressive therapy for severe disease, have been used with varying rates of success. Using topical tacrolimus, an immunosuppressant that inhibits T-lymphocyte proliferation, and meticulous stoma care can result in successful treatment. Two women (ages 59 and 62 years) with a history of ulcerative colitis and colon resection presented with parastomal ulcers consistent with PPG. The 59-year patient presented with a painful 2 cm x 2 cm parastomal ulcer that improved following daily application of topical tacrolimus 0.1%. The 62-year old woman first was prescribed daily appliance changes and application of topical triamcinolone 0.5% to her 3-cm ulcer. The ulcer increased in size and treatment was changed to daily application of tacrolimus 0.1%. After 2 months and a reduction in ulcer size and severity, the dosage was changed to daily application of tacrolimus 0.03%. Both patients reported resolution of pain and itching, the most common symptoms of PPG, and no adverse effects were observed. The encouraging results observed in these two cases confirm that tacrolimus helps resolve PPG lesions even at concentrations previously thought to be ineffective. Additional studies to help clinicians optimize care of these painful lesions are needed. Key Words: colostomy, pyoderma gangrenosum, tacrolimus, parastomal ulcer Index: Ostomy Wound Management 2010;56(9):xx xx Potential Conflicts of Interest: The authors have nothing to disclose. Pyoderma gangrenosum (PG) was first described by Brunsting et al 1 in 1930 as an idiopathic, ulcerative, inflammatory dermatologic condition that occurs in approximately 1% to 5% of patients with inflammatory bowel disease (IBD). PG also has been described in patients with systemic disease such as cancer, Hodgkin's, hepatitis, rheumatoid arthritis, and hematological disorders. This inflammatory skin disorder is presumably caused by an autoimmune mechanism and usually appears as painful pustules that can progress to ulceration with a violaceous border, which heals into a cribiform scar. 2 The lesions predominantly occur on the extensor surfaces of the extremities, most commonly in the pretibial region, but also can occur along incisions, in areas of trauma, and around stomas. 3 The diagnosis is one of exclusion because no microbiological organisms are found and biopsy reveals a nonspecific inflammatory reaction with dermal neutrophilia. Parastomal pyoderma gangrenosum (PPG) was reported by Margoles and Wenger 4 in ulcerative colitis and by McGarity et al 5 in Crohn s disease. Although PG is not a common condition, it is thought to account for approximately 50% of Ms. Altieri is an MSIV and Dr. Vaziri is an Assistant Professor of Surgery, The George Washington University Medical Center, Washington, DC.Dr. Orkin is Chief, Colon and Rectal Surgery and Professor of Surgery, Tufts University Medical Center, Boston, MA. Please address correspondence to: Khashayar Vaziri, MD, The George Washington University Medical Center, 2150 Pennsylvania Avenue NW, Suite 6B, Washington, DC 20037; kvaziri@mfa.gwu.edu. 32 OSTOMY WOUND MANAGEMENT SEPTEMBER
2 TOPICAL TACROLIMUS FOR PARASTOMAL PYODERMA GANGRENOSUM chronic parastomal ulcers. Frequently misdiagnosed, the actual incidence of this disorder is difficult to confirm. PPG Management PPG is particularly difficult to manage, especially in refractory cases. The successful treatment of PPG involves healing of the ulcer and control of ostomy function with meticulous stoma management. The treatment regimen is based on individual response and can be local, systemic, or in some refractory cases, surgical. Local treatment includes wound care, topical agents, and local injection of medications. Local wound care including debridement, curettage, and deroofing the ulcer complex is often insufficient. Unsuccessful treatment can result in stoma relocation. 6 Use of topical agents including antibiotics, corticosteroids, Desitin ointment (Pfizer, Inc., New York, NY), and 0.5% nicotine cream has been described and provides variable efficacy. 7 Systemic therapy such as dapsone, prednisone, cyclosporine, mycophenolate mofetil, and intravenous infliximab remain the mainstay of treatment In refractory cases or in patients with inactive or resected disease, topical tacrolimus can be beneficial. Tacrolimus (FK506) is a potent member of the macrolide family of immunosuppressive antibiotics. It acts by blocking the IL-2 transcription, thereby inhibiting T-lymphocyte proliferation and activation. Systemic therapy with tacrolimus has been shown to be effective in a variety of lymphocyte-driven inflammatory dermatoses, although adverse effects of the systemic treatment such as hypertension, neurotoxicity, and nephrotoxicity have been shown. 11 In order to circumvent the adverse effects of systemic therapy, topical treatment strategies have been evaluated in multiple case studies. Studies 19,20 using 0.3% tacrolimus ointment report rare adverse reactions, such as burning, pruritis, flu-like symptoms, allergic reactions, and skin erythema. Manufacturer contraindications for the use of tacrolimus include a known allergy to tacrolimus or one of the components of the preparation. Tacrolimus should not be used in the pediatric population or on any lesion of infectious origin. Applied topically, tacrolimus penetrates skin effectively and has been used in a wide array of inflammatory dermatoses, such as graft versus host disease, vitiligo, contact dermatitis, and alopecia Results of case series 16,17 indicate that topical tacrolimus has been one of the more effective local agents in the treatment of PG. 16,17 Schuppe et al 16 reported a case of a 32-year-old woman who developed a rapidly growing ulcer on her right calf. On admission, the ulcer had a 10-cm diameter and showed typical features of PG. Although ulcer enlargement ceased with standard treatment with oral prednisolone (100 mg daily), healing was achieved after 2 weeks of daily topical applications of tacrolimus (0.5% solution). The authors used topical tacrolimus alone under a hydrocolloidal wound dressing. The skin lesion completely resolved at 12 weeks after discontinuation of the steroids. No adverse effect other than a burning sensation was noted. Reich Ostomy Wound Management 2010;56(9):xx xx Key Points Parastomal lesions present unique diagnostic and management challenges. Parastomal pyoderma gangrenosum (PPG) lesions are often refractive to treatment and painful. The authors describe good outcomes with the daily application of low-dose (0.1% and 0.03%) tacrolimus ointment in two patients with PPG. et al 17 described two cases where patients with PG were treated successfully with tacrolimus ointment alone and in combination with systemic cyclosporine. The first case involved a 48- year-old man with recurrent ulcerative lesions. Although previous lesions had responded to traditional treatment comprising systemic prednisolone and low-dose cyclosporine, the recurrent lesions failed to respond. When the patient developed a 2-cm lesion over the clavicle, the authors started monotherapy consisting of twice-daily application of tacrolimus ointment (0.1%). The lesion healed in 3 weeks. The second patient, a 27-year-old woman with a 4-year history of ulcerative colitis, presented with several lesions ranging from 5 cm to 10 cm in diameter. This patient was treated with systemic cyclosporine at 5 mg/kg/day, which was tapered, and 0.1% tacrolimus ointment applied once daily with a hydrocolloid dressing for 3 weeks. The authors concluded that the addition of tacrolimus accelerated lesion healing. D Inca et al 18 described oral tacrolimus as an effective and safe treatment for highly destructive cyclosporine-resistant PG. In this case, oral therapy with tacrolimus (0.1 mg/kg per day) was started following an unsuccessful course of cyclosporine and antibiotics in the attempt to treat a 15-cm area of necrotic tissue. To compare treatment with topical tacrolimus and clobetasol propionate, Lyons et al 19 followed 30 patients with PPG. Topical tacrolimus 0.3% in Orabase (ConvaTec Ltd., Uxbridge, Middlesex, UK) was given to six patients who had failed to respond to topical corticosteroids, systemic corticosteroids, or cyclosporine. In five of the six patients, PPG healed within 6 weeks following application and the last patient was controlled with systemic tacrolimus. The authors concluded that tacrolimus is an effective treatment in ulcers >2 cm. Furthermore, based on the results observed in 11 patients, they found that treatment with tacrolimus in concentrations less than 0.3% was ineffective. This article presents two cases in which topical tacrolimus 0.1% was used successfully in the treatment of PPG. Case Report 1 Ms. A, a 59-year-old woman with a medical history unremarkable other than for pan-ulcerative colitis, underwent a colonoscopy that revealed multiple polyps. The majority of the biopsies performed revealed chronic colitis without dys- SEPTEMBER 2010 OSTOMY WOUND MANAGEMENT 33
3 Figure 1. Case 1: parastomal ulceration upon presentation. Figure 2. Case 1: 6 weeks after therapy with topical tacrolimus. Figure 3. Case 1: 2 months after therapy. plasia. One 4 cm x 5cm polyp in the region of the sigmoid and descending colon was described as a dysplasia-associated lesion or mass (DALM). A total proctocolectomy with end ileostomy was performed. Postoperatively, Ms. A recovered well and did not require any further post-resection medical treatment but 11 months later, Ms. A noticed two small ulcers on the right side of the stoma. These developed into an irregular shaped 2 cm x 2 cm painful ulcer with raised edges and a violet hue in one area of the wound border (see Figure 1). The lesion was clinically identified as PPG. Ms. A was prescribed daily appliance changes and application of topical tacrolimus 0.1 % ointment. No special parastomal skin care preparations were used and the ointment was placed directly under the adhesive pouch. Six weeks later, the lesion had markedly improved with new skin forming on the lower edge of the parastomal ulcer and a healthy stoma (see Figure 2). Ms. A s treatment was altered to tacrolimus ointment 0.03% ointment and every-other-day appliance changes. The dosage was lowered and appliance changes were performed in this frequency to ensure use of the minimal concentration tacrolimus and to reduce parastomal trauma from frequent appliance changes. Two months later, the PPG had improved substantially and itching and pain had resolved (see Figure 3). Ms. A experienced a brief resurgence of her symptoms and skin changes with an unintended hiatus in her therapy. She was restarted on topical tacrolimus 0.1% ointment and after a few weeks of therapy, her symptoms resolved. Case Report 2 Ms. B, a 62-year-old woman with a history of chronic ulcerative colitis who underwent a total proctocolectomy and ileostomy due to pan-colitis, DALM, and poor sphincter function presented with pain, bleeding, and ulceration around her right lower quadrant ileostomy after trauma to her stoma. Her medical history was otherwise unremarkable. Examination revealed a healthy ileostomy with a tender, 1 cm x 1 cm ulcerated skin lesion on the right side of the stoma with raised edges clinically consistent with PG (an infectious etiology was not found). Therapy with topical triamcinolone 0.5% and daily appliance changes was initiated. However, this treatment was unsuccessful and the ulcerative process progressed. After 1 month, Ms. B s lesion had enlarged to a 3-cm ulceration with excoriation of the left lateral and left inferior parastomal skin. Daily appliance changes and topical application of tacrolimus 0.1% ointment were prescribed. Over a few weeks, rapid improvement was noted and the tacrolimus was decreased to 0.03% concentration after 2 months along with careful monitoring by the enterostomal therapist and daily appliance changes. The ulcer and areas of excoriation were completely healed 4 months after topical tacrolimus therapy was initiated. Discussion In both cases of patients presenting with PPG, topical tacrolimus 0.1% was effective, confirming previous reports about the usefulness of topical tacrolimus in the management of refractory PPG in ulcerative colitis and Crohn s disease. 19,20 In both cases, after improvement of the lesions with use of topical tacrolimus 0.1%, tacrolimus 0.03% was able to be used until complete resolution. No side effects such as a burning sensation, erythema, or pruritus were noted. 34 OSTOMY WOUND MANAGEMENT SEPTEMBER
4
5 The time between stoma creation and onset of the lesion is variable. Development of PPG is believed to be related to underlying IBD; therefore, control of the underlying disease should result in lesion improvement. As mentioned previously, the successful treatment of PPG involves not only ulcer healing but also successful stoma management. For this reason, PPG treatment can be an immediate and ongoing challenge as lesion healing may result in irregular scarring, which can compromise proper fitting of the appliance and lead to leakage. The results of several observational studies have shown that topical tacrolimus may cause hyper-granulation tissue to develop in healing ulcers, possibly through a mechanism involving granulocyte-macrophage colony stimulating factor (GM-CSF). 19 GM-CSF is a cytokine that promotes white blood cell production and granulation tissue formation. The presence of hypergranulation tissue also affects stoma appliance adhesion. Lyons et al 19 addressed these concerns by adding topical corticosteroids in the form of an impregnated tape to the treatment with topical tacrolimus to help protect the ulcer from trauma by the tape and limit over-granulation with the corticosteroid. In Lyons study, tacrolimus 0.3% in carmellose sodium paste was used and it was concluded that concentrations <0.3% were not effective. Baig et al 20 described two cases of PPG in Crohn s disease that were successfully treated with 0.01% topical tacrolimus; both patients in the current case study responded well to a concentration of 0.1%. The reasons for the efficacy of different doses are unknown. Possible explanations may be related to the extent and severity of disease. In all cases, successful treatment relies on diligent ostomy care. No prognostic indicators of successful treatment have been noted other than clinical response to therapy. Similarly, results of recurrent application, required by one of the current study patients, has not been widely reported. Obstacles to successful treatment of PPG, such as stoma appliance adherence, can be overcome without much difficulty. Conclusion Two case reports concur with the available literature regarding successful treatment of PPG with topical tacrolimus. Although PPG is rare and large randomized trials are unavailable, topical tacrolimus used in conjunction with good stoma care can be a useful and successful treatment strategy for refractory PPG. References 1. Brunsting LA, Goeckerman WH, O Leary, PA. Pyoderma gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syphilol. 1930;22: Callen JP. Pyoderma gangrenosum. Lancet. 1998;351: Bennett ML, Jackson JL, Jorizzo JL, et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from two institutions. Medicine. 2000;79: Margoles JS, Wenger J. Stomal ulceration associated with pyoderma gangrenosum and chronic ulcerative colitis. Report of two cases. Gastroenterol. 1961;41: McGarity WC, Robertson DB, McKeown PP, et al. Pyoderma gangrenosum at the parastomal site in patients with Crohn s disease. Arch Surg. 1984;119(10): Yeo H, Abir F, Longo WE. Management of parastomal ulcers. World J Gastroenterol. 2006;12(20): Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of parastomal pyoderma gangrenosum. JAMA. 2000;284(12): Powell RJ, Holbrook MR, Stevens A. Pyoderma gangrenosum and its treatment. Lancet. 1997;350( 9093): Poritz, LS, Lebo MA, Bobb AD, et al. Management of parastomal pyoderma gangrenosum. J Am Coll Surg. 2008;206: Daniels NH, Callen JP. Mycophenolate mofetil is an effective treatment for parastomal pyoderma gangrenosum. Arch Dermatol. 2004;140: Callen PC, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin N Am. 2007;33: Price V, Willey A, Chen B. Topical tacrolimus in alopecia areata. JAAD. 2005;52(1): Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease. A case series of 18 patients. Arch Dermatol. 2001;137: Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. JAAD. 2002;47(5): Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. New Engl J Med. 1997;337(12): Schuppe HC, Homey B, Assmann T, et al. Topical tacrolimus for pyoderma gangrenosum. Lancet. 1998;351: Reich K, Vente C, Neumann C. Treatment of pyoderma gangrenosum with topical tacrolimus. Br J Dermatol. 1998;139(4): D Inca R, Fagiuoli S, Sturniolo GC. Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine. Ann Int Med. 1998;128(9): Lyon CC, Stapleton M, Smith AJ, et al. Topical tacrolimus in the management of parastomal pyoderma gangrenosum. J Dermatol Treat. 2001;12: Baig MK, Marquez H, Nogueras JJ, et al. Topical tacrolimus (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn s disease: report of two cases. Colorect Dis. 2004;6: OSTOMY WOUND MANAGEMENT SEPTEMBER
Case 1 History. William Tremaine, M.D. CP
Extraintestinal Manifestations of IBD Case Studies William Tremaine, M.D. Case 1 History 18 year-old woman with Crohn s disease Onset at age 5: colonic & perianal Sulfasalazine, prednisone, mercaptopurine
More informationLynn E. DeMartyn, BSN, RN, CWOCN; Nancy Ann Faller, RN, MSN, PhD, CWOCN; and Laurie Miller, RN, BSN, CWOCN
Treating Peristomal Pyoderma Gangrenosum With Topical Crushed Prednisone: A Report of Three Cases Lynn E. DeMartyn, BSN, RN, CWOCN; Nancy Ann Faller, RN, MSN, PhD, CWOCN; and Laurie Miller, RN, BSN, CWOCN
More informationInfliximab: A Treatment Option for Ulcerative Pyoderma Gangrenosum
To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/449955 Infliximab: A Treatment Option for Ulcerative Pyoderma Gangrenosum
More informationManagement of Pyoderma Gangrenosum Mentoring in IBD XVII
Management of Pyoderma Gangrenosum Mentoring in IBD XVII Scott Walsh MD PhD FRCPC Division of Dermatology Sunnybrook Health Sciences Centre University of Toronto Pyoderma Gangrenosum: A pathological
More informationCASE REPORT ATYPICAL BULLOUS PYODERMA GANGRENOSUM WITH EARLY LESIONS MIMICKING CHICKEN POX
ATYPICAL BULLOUS PYODERMA GANGRENOSUM WITH EARLY LESIONS MIMICKING CHICKEN POX Ramesh M 1, Kavya Raju Nayak 2, M.G. Gopal 3, Sharath Kumar B.C 4, Nandini A.S 5 HOW TO CITE THIS ARTICLE: Ramesh M, Kavya
More informationPyoderma gangrenosum presenting with acute generalised haemorrhagic bullae
H.K. Dermatol. Venereol. Bull. (2003) 11, 155-159 Case Report Pyoderma gangrenosum presenting with acute generalised haemorrhagic bullae YH Chan, WYM Tang, WY Lam A 31-year-old Chinese man presented with
More information2019 update on pyoderma gangrenosum
2019 update on pyoderma gangrenosum Kanade Shinkai, MD PhD University of California, San Francisco F106: Updates in neutrophilic and pustular dermatoses I have no conflicts of interest to disclose. I will
More informationRecognizing Pyoderma Gangrenosum in a Patient with History of Essential Thrombocytosis
Open Journal of Clinical & Medical Case Reports Volume 2 (2016) Issue 17 ISSN 2379-1039 Recognizing Pyoderma Gangrenosum in a Patient with History of Essential Thrombocytosis * Amier Ahmad, Md ; Kevin
More informationPAPER. Twenty Cases of Peristomal Pyoderma Gangrenosum. David G. Sheldon, MD; Lynda L. Sawchuk, ARNP; Richard A. Kozarek, MD; Richard C.
Twenty Cases of Peristomal Pyoderma Gangrenosum Diagnostic Implications and Management PAPER David G. Sheldon, MD; Lynda L. Sawchuk, ARNP; Richard A. Kozarek, MD; Richard C. Thirlby, MD Hypothesis: Our
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Ulcerative colitis: the management of ulcerative colitis Quality standard title: Ulcerative
More informationInflammatory Bowel Disease: Updates and Controversies CASE #1 CASE #1 8/6/2015. What is the most likely diagnosis?
Inflammatory Bowel Disease: Updates and Controversies Tehttp://192.185.93.102/~paulkeij/wpcontent/uploads/2013/07/collaboration.jpgxt August 7, 2015 Meagan M Costedio, MD; Colorectal Surgery; Cleveland
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationSuperficial Granulomatous Pyoderma of the Face: A Case Report and Review of the Literature
Superficial Granulomatous Pyoderma of the Face: A Case Report and Review of the Literature Sarah M. Persing, MPH, a and Donald Laub Jr, MD, FACS a,b a University of Vermont College of Medicine, Burlington;
More informationPyoderma Gangrenosum Associated with Ulcerative Colitis
2006;14(1):35-39 CASE REPORT Pyoderma Gangrenosum Associated with Ulcerative Colitis Suzana Ljubojević 1, Višnja Milavec-Puretić 1, Vesna Sredoja-Tišma 2, Jaka Radoš 1, Mirjana Kalauz 3, Irena Hrstić 3
More informationPyoderma gangrenosum rare manifestation of crohn s disease in 14 year old child: Case report
Damor et al. 46 CASE REPORT OPEN ACCESS Pyoderma gangrenosum rare manifestation of crohn s disease in 14 year old child: Case report Ajay Damor, Varsha Shah, Lalit Nainiwal, Bhadra Trivedi, Rohit Agrawal,
More informationInteresting Case Series. Skin Grafting in Pyoderma Gangrenosum
Interesting Case Series Skin Grafting in Pyoderma Gangrenosum Marco Romanelli, MD, PhD, Agata Janowska, MD, Teresa Oranges, MD, and Valentina Dini, MD, PhD Department of Dermatology, University of Pisa,
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationSurgery for Inflammatory Bowel Disease
Surgery for Inflammatory Bowel Disease Emily Steinhagen, MD Assistant Professor Department of Surgery, Division of Colorectal Surgery University Hospitals Cleveland Medical Center Common Questions Why
More informationA practical guide for Peristomal Skin problems. Developed by the Ostomy Forum. Dedicated to Stoma Care
A practical guide for Peristomal problems Developed by the Ostomy Forum Dedicated to Stoma Care E24-82-300 03/09 2009 Dansac A/S Lindegaard & Co For outstanding contribution towards making this project
More informationInflammation in the clinic
Inflammation in the clinic Stephen T. Holgate MRC Clinical Professor of Immunopharmacology ILSI Europe Workshop, Seville, May 14-15 2012 The immune system acts in four general ways to ensure host defence
More informationWhat is ulcerative colitis?
What is ulcerative colitis? Ulcerative colitis is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. Ulcers form where inflammation has killed the cells
More informationSURGICAL MANAGEMENT OF ULCERATIVE COLITIS
SURGICAL MANAGEMENT OF ULCERATIVE COLITIS Cary B. Aarons, MD Associate Professor of Surgery Division of Colon & Rectal Surgery University of Pennsylvania AGENDA Background Diagnosis/Work-up Medical Management
More informationAtopic Dermatitis: Therapeutic Challenges
Atopic Dermatitis: Therapeutic Challenges PDA August 14, 2009 Jon Hanifin OHSU, Portland Dominant Concepts in Atopic Dermatitis Allergy / Immunology Era: 1915-2006 The Epidermal Era: 2006---- Barrier dysfunction
More informationVitiligo is a skin depigmentation disorder
THERPEUTICS FOR THE CLINICIN Tacrolimus Ointment 0.1% Produces Repigmentation in Patients With Vitiligo: Results of a Prospective Patient Series Emil. Tanghetti, MD The cause of the selective melanocyte
More informationSurgical Treatment of Inflammatory Bowel Disease (IBD)
Surgical Treatment of Inflammatory Bowel Disease (IBD) JMAJ 45(2): 55 62, 2002 Tetsuichiro MUTO Vice-Director, Cancer Institute Hospital Abstract: IBD, especially ulcerative colitis (UC) and Crohn s disease
More informationInflammatory Bowel Disease and Surgery: What You Should Know
Inflammatory Bowel Disease and Surgery: What You Should Know Ask the Experts March 9, 2019 Kristen Blaker, MD Colon and Rectal Surgery MetroHealth Medical Center Disclosures None Outline Who undergoes
More informationThe role of Surgery and Stomas in IBD
The role of Surgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it? Kyle G. Cologne, MD Assistant Professor of Surgery USC Division of Colorectal Surgery Topics Surgical Differences
More informationWHAT IS ULCERATIVE COLITIS?
235 60th Street, West New York, NJ 07093 T: (201) 854-4646 F: (201) 854-4647 810 Main Street, Hackensack, NJ 07601 T: (201) 488-0095 Ulcerative Colitis WHAT IS ULCERATIVE COLITIS? Ulcerative colitis is
More informationDISCLOSURES WHAT S NEW AND EXCITING FROM JAAD
WHAT S NEW AND EXCITING FROM JAAD Bruce H. Thiers, MD, Editor, JAAD Professor, Medical University of South Carolina Department of Dermatology and Dermatologic Surgery DISCLOSURES PFIZER VALEANT EFFECT
More informationCase 1. Debridement Cultures Keflex Silvadene
The Red Breast Beth McLellan, M.D. Assistant Professor Division of Dermatology Albert Einstein College of Medicine Montefiore Medical Center Jacobi Medical Center Case 1 48 year old radiation oncologist
More informationTreatment with steroids and immunosuppressants
Treatment with steroids and immunosuppressants Donna Culton, MD, PhD University of North Carolina IPPF 2017 Annual Patient Conference Newport Beach, CA September 16, 2017 Factors that will influence therapy
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 1.5 Chronic Bowel Disorders (including IBD) Aminosalicylates: Mesalazine 400mg and 800mg MR Tablets (Octasa) Mesalazine 1.2g MR Tablets (Mezavant XL) Mesalazine
More informationULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC
ULCERATIVE COLITIS Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC What is Ulcerative Colitis? Ulcerative colitis (UC) is a disease marked by inflammation
More informationAbdominal Wall Modification for the Difficult Ostomy
Abdominal Wall Modification for the Difficult Ostomy David E. Beck, M.D. 1 ABSTRACT A select group of patients with major stomal problems may benefit from operative modification of the abdominal wall.
More informationSurgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it?
Surgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it? Kyle G. Cologne, MD Assistant Professor of Surgery USC Division of Colorectal Surgery Topics Surgical Differences between
More informationColostomy & Ileostomy
Colostomy & Ileostomy Indications, problems and preference By Waleed Omar Professor of Colorectal surgery, Mansoura University. Disclosure I have no disclosures. Presentation outline Stoma: Definition
More informationSTOMA SITING & PARASTOMAL HERNIA MANAGEMENT
STOMA SITING & PARASTOMAL HERNIA MANAGEMENT Professor Hany S. Tawfik Head of the Department of Surgery & Chairman of Colorectal Surgery Unit Benha University Disclosure No financial affiliation to disclose
More informationOPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS
OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS Alberto Fusi Charité Comprehensive Cancer Centre Berlin, Germany 1 Immune check point blockade with CTLA-4, anti-pd-1
More informationDecision relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin)
9 September 2015 Decision relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin) The PHARMAC Board has approved the proposal relating to the funding of the TNF-inhibitor
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationPyoderma gangrenosum: A clinico- therapeutic profile of patients attending a tertiary care hospital in Nepal
Journal of College of Medical Sciences-Nepal, 2012, Vol-8, No-1, 29-35 Original Article Pyoderma gangrenosum: A clinico- therapeutic profile of patients attending a tertiary care hospital in Nepal C. Kharel
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationHammer Toe. Photo Diagnosis. Case 1. Illustrated quizzes on problems seen in everyday practice. Questions. Answers
Illustrated quizzes on problems seen in everyday practice Hammer Toe Case 1 This 48-year-old gentleman has a long history of Rheumatoid arthritis, for which he has been on Methotrexate 10 mg weekly for
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationDisclosure of Affiliations. The Way We Hope It Goes. Medicines and Surgery for IBD. None. Cases: Sweet and Not So Sweet
Immunomodulators and Complications of Surgery for Inflammatory Bowel Disease Disclosure of Affiliations None Thomas E. Read, MD, FACS, FASCRS Professor of Surgery Tufts University School of Medicine Senior
More informationДоверяй, но проверяй {Doveryai, no proveryai} Trust, but Verify. Jeffrey P. Callen, MD Professor of Medicine (Dermatology) University of Louisville
Доверяй, но проверяй {Doveryai, no proveryai} Trust, but Verify Jeffrey P. Callen, MD Professor of Medicine (Dermatology) University of Louisville Jeffrey P. Callen, MD Disclosure (previous 12 months)
More informationWhat's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More informationDose of prednisone for allergic reaction
Dose of prednisone for allergic reaction Medical uses. Prednisone is used for many different autoimmune diseases and inflammatory conditions, including: asthma, COPD, CIDP, rheumatic disorders, allergic.
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
More informationMegha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics, Mayo Clinic Pediatric Morphea March 1, MFMER
Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics, Mayo Clinic Pediatric Morphea March 1, 2019 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Topics to cover Classification
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationSurgical Therapies for the Treatment of IBD!
Surgical Therapies for the Treatment of IBD! Andrew A Shelton, MD Clinical Professor of Surgery Stanford Hospital and Clinics Section of Colon and Rectal Surgery! Ulcerative Colitis v. Crohn s! 30% of
More informationRisk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease,
Journal of Crohn's and Colitis (2013) 7, e171 e177 Available online at www.sciencedirect.com Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease, Xian-rui Wu a, b,
More informationPSEUDO-CELLULITIS - ALL THAT S RED IS NOT INFECTION
JAN 18 2018 ASP ECHO CLINIC CHARLES KRASNER, M.D. PSEUDO-CELLULITIS - ALL THAT S RED IS NOT INFECTION FIRST HOSPITALIZATION: 62 YEAR OLD MALE ADMITTED WITH DIAGNOSIS OF CELLULITIS Hx of AODM, Morbid Obesity,
More informationTHE TIP OF THE ICEBERG SAMER BOLIS, DO PGY-3 LEHIGH VALLEY HEALTH NETWORK, ALLENTOWN PA
THE TIP OF THE ICEBERG SAMER BOLIS, DO PGY-3 LEHIGH VALLEY HEALTH NETWORK, ALLENTOWN PA Case The patient is a 48 year-old female, who recently returned from a trip to Puerto Rico. She presents to the ED
More informationIndex. Surg Clin N Am 87 (2007) Note: Page numbers of article titles are in boldface type.
Surg Clin N Am 87 (2007) 787 796 Index Note: Page numbers of article titles are in boldface type. A Abscesses in anorectal Crohn s disease, 622 intra-abdominal, in Crohn s disease, 590 591 perirectal,
More informationAdalimumab Therapy for Recalcitrant Pyoderma Gangrenosum
Adalimumab Therapy for Recalcitrant Pyoderma Gangrenosum Margaret A. Fonder, BS, Deborah L. Cummins, MD, Benjamin D Ehst, MD, PhD, Grant J. Anhalt, MD, and Jon H. Meyerle, MD From the Department of Dermatology,
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationCrohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine
Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More informationFuture of Pediatrics: Blisters, Hives and Other Tales from the Emergency Room June 14 th, 2016
A. Yasmine Kirkorian MD Assistant Professor of Dermatology & Pediatrics Children s National Health System George Washington University School of Medicine & Health Sciences Future of Pediatrics: Blisters,
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationTopical tacrolimus may be evective in the treatment of oral and perineal Crohn s disease
436 Gut 2000;47:436 440 CASE REPORT University Paediatric Gastroenterology, Royal Free and University College School of Medicine, London, UK D H Casson J A Walker-Smith S H Murch Pharmacy, Royal Free and
More informationChallenging Cases in Dermatopathology. Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania
Challenging Cases in Dermatopathology Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Rosalie Elenitsas
More informationPrescribing Information
Prescribing Information Pr DERMOVATE Cream (clobetasol propionate cream, USP) Pr DERMOVATE Ointment (clobetasol propionate ointment, USP) Topical corticosteroid TaroPharma Preparation Date: A Division
More informationDrug allergy and Skin Disorders. Timothy Craig, DO, FACOI Professor of Medicine and Pediatrics Distinguished Educator Penn State University, Hershey
Drug allergy and Skin Disorders Timothy Craig, DO, FACOI Professor of Medicine and Pediatrics Distinguished Educator Penn State University, Hershey The best screening test for anaphylaxis is? A. histamine
More informationSurgical Management of IBD. Val Jefford Grand Rounds October 14, 2003
Surgical Management of IBD Val Jefford Grand Rounds October 14, 2003 Introduction Important Features Clinical Presentation Evaluation Medical Treatment Surgical Treatment Cases Overview Introduction Two
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abatacept for DLE, 493 for SLE, 497 Ablative therapies, localized, for cutaneous T-cell lymphoma, 502 506. See also Cutaneous T-cell lymphoma,
More informationGuideline Ulcerative colitis: management
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline Ulcerative colitis: management Draft for consultation, December 0 This guideline covers the care and treatment of adults, children and young
More informationPrimary Sclerosing Cholangitis Medical Management
Primary Sclerosing Cholangitis Medical Management Kapil Chopra M.D. Assistant Professor of Medicine Division of Transplant Medicine Mayo Clinic Arizona PSC Primary sclerosing cholangitis is a progressive
More informationThe Role of Surgery in Inflammatory Bowel Disease. Cory D Barrat, MD Colon and Rectal Surgeon Mercy Health
The Role of Surgery in Inflammatory Bowel Disease Cory D Barrat, MD Colon and Rectal Surgeon Mercy Health THANKS FOR INVITING ME! I have no financial disclosures Outline - Who am I and what do I do? -
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationPrimary Adenocarcinoma of an Ileostomy in Crohn's Disease.
Primary Adenocarcinoma of an Ileostomy in Crohn's Disease. Kevin Liu, Northwestern University Meena Prasad, Emory University Amy Lo, Stanford University Emanuelle Bellaguarda, Northwestern University Scott
More informationSerologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I
Autoimmune Hepatitis By Thomas Frazier Objective What we need to know about AIH Diagnosis Treatment Difficulties in both Liver transplantation concerns AASLD Guidelines: Hepatology. 2010 Jun;51(6):2193-213.
More informationSkin/Wound Issues Why Things Go Wrong. Dane De Luca RN BSN WOCN
Skin/Wound Issues Why Things Go Wrong Dane De Luca RN BSN WOCN Skin Issue Topics O Incontinence O Leakage from tubes O Products available to protect the skin O Management of tube leakage Incontinence Associated
More informationDOI: /EP AACE
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationContact Dermatitis In Atopic Patients
Contact Dermatitis In Atopic Patients Jenny Murase, MD Palo Alto Foundation Medical Group Director of Patch Testing University of California, San Francisco Associate Clinical Professor Disclosures Consultant
More informationMore Non-infectious Granulomatous Diseases! Karolyn Wanat, MD Assistant Professor, Dermatology & Pathology University of Iowa
More Non-infectious Granulomatous Diseases! Karolyn Wanat, MD Assistant Professor, Dermatology & Pathology University of Iowa Conflicts of Interest/Disclosure None Classification/Overview 1) Necrobiotic/Palisading
More informationProposal relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin)
14 July 2015 Proposal relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin) PHARMAC is seeking feedback on a proposal relating to the funding of the TNF-inhibitor medicines
More informationAutoimmune Hepatitis. What Drug and for How Long? Hepatology Day May 30 th, 2015
Autoimmune Hepatitis What Drug and for How Long? Rajaa Chatila, MD Associate Professor of Medicine Director, Internal Medicine Residency Program Lebanese American University Hepatology Day May 30 th, 2015
More informationComplications of Immunotherapy
Complications of Immunotherapy Sarah Norskog, PharmD, BCOP Oncology Pharmacy Specialist University of Colorado Hospital Disclosures I have no relevant financial relationships with commercial interests
More informationAssessing the Current Treatment of Atopic Dermatitis: Unmet Needs
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationA Vitiligo Update for Pharmacists: Current Practices and Future Advances
A Vitiligo Update for Pharmacists: Current Practices and Future Advances Dalal Hammoudi Halat, RPh, MSc, PhD Assistant Professor School of Pharmacy, Lebanese International University Disclosure Dalal Hammoudi
More information11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery
Biologics for CD and CUC: The Impact on Surgical Outcomes Robert R. Cima, M.D., M.A. Associate Professor of Surgery Division of Colon and Rectal Surgery Overview Antibody based medications (biologics)
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationPrior Authorization Conditions for Approval of Humira (adalimumab) Website Form Submit request via: Fax
Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Humira (adalimumab) require a prior
More informationCiclosporin Microemulsion for Severe Atopic Dermatitis: Experience on Adolescents and Adults in Hong Kong
ORIGINAL ARTICLES Ciclosporin Microemulsion for Severe Atopic Dermatitis: Experience on Adolescents and Adults in Hong Kong Drs. H. F. Ho, L.Y. Chong, K. M. Ho and W. K. Fung Social Hygiene Service (Dermatology),
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationPrescribing Information. Taro-Clobetasol. Taro-Clobetasol
Prescribing Information Pr Taro-Clobetasol Clobetasol Propionate Cream USP, 0.05% w/w Pr Taro-Clobetasol Clobetasol Propionate Ointment USP, 0.05% w/w Therapeutic Classification Topical corticosteroid
More informationPercent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =
Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence
More informationLiving Well With an Ostomy. Maggie Bork, RN, BSN, CWOCN
Living Well With an Ostomy Maggie Bork, RN, BSN, CWOCN Objectives 1. Describe the 3 most common types of ostomies. 2. Discuss the results of recent research studies related to peristomal and stoma challenges.
More informationSurgical Management of IBD in the Age of Biologics
Surgical Management of IBD in the Age of Biologics Lisa S. Poritz, M.D Associate Professor of Surgery Division of Colon and Rectal Surgery Objectives Discuss surgical management of IBD When to operate
More informationCrohn's Disease. What causes Crohn s disease? What are the symptoms?
Crohn's Disease Crohn s disease is an ongoing disorder that causes inflammation of the digestive tract, also referred to as the gastrointestinal (GI) tract. Crohn s disease can affect any area of the GI
More informationGalen ( A.D) Advanced Wound Dressing
Galen (120-201A.D) Advanced Wound Dressing Wounds heal optimally in a moist environment นพ.เก งกาจ ว น ยโกศล Wound assessment Ideal wound dressing Type of wound Clinical appearance Wound location Measurement
More information9/10/2018. No financial or off label use disclosures. 1. Describe skin problems for an ostomate and interventions for management
Debra Netsch DNP,APRN,FNP-BC,CWOCN-AP,CFCN WEB WOC Nurse Education Programs: Co-Director & Faculty Ridgeview Medical Center, Wound & Hyperbaric Clinic: NP & CWOCN-AP JWOCN: Clinical Challenges Section
More informationColorectal Surgery. Patient Care. Goals and Objectives
Colorectal Surgery Patient Care 1) Interpret the results of clinical evaluations (history, physical examination) performed on patients with a) Hemorrhoids b) Perianal abscess/fistula c) Anal fissure d)
More informationPost Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.
Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for
More information